# Chronic Pancreatitis

## Definition and Pathogenesis

### Definition

Chronic pancreatitis is a progressive inflammatory disease characterized by irreversible structural changes to the pancreas, including fibrosis, calcification, and ductal distortion, which ultimately lead to exocrine and/or endocrine insufficiency. It is distinct from recurrent acute pancreatitis, although recurrent acute pancreatitis often precedes chronic pancreatitis, consistent with the sentinel acute pancreatitis event model of disease progression.

### Pathogenesis — TIGAR-O Classification

The TIGAR-O classification organizes the etiologies of chronic pancreatitis into six categories.

| Category | Examples | Key Features |
|---|---|---|
| Toxic-metabolic | Alcohol (60-70%), smoking, hypertriglyceridemia, hypercalcemia, CKD, medications | Alcohol: >80 g/day for 6-12 years; smoking: 2-3x risk, synergistic with alcohol |
| Idiopathic | Early-onset, late-onset, tropical pancreatitis | Tropical: young onset, large duct stones, high malignancy risk |
| Genetic | PRSS1, SPINK1, CFTR, CTRC, CPA1, CLDN2 | PRSS1: autosomal dominant, 80% penetrance, 40% lifetime pancreatic cancer risk |
| Autoimmune | Type 1 (IgG4-related), Type 2 (duct-centric) | Type 1: elderly males, systemic; Type 2: younger, IBD-associated |
| Recurrent/severe AP | Post-acute pancreatitis progression | 36% progress to CP, especially with continued alcohol/smoking |
| Obstructive | Tumors, strictures, pancreas divisum | Duct obstruction with upstream changes |

Toxic-metabolic causes include alcohol, which accounts for 60 to 70% of cases in Western countries and typically requires consumption exceeding 80 grams per day for 6 to 12 years. Smoking is an independent risk factor with a 2- to 3-fold increase in risk and demonstrates a synergistic effect with alcohol. Hypertriglyceridemia, hypercalcemia, chronic kidney disease, and medications are also classified within this category.

Idiopathic chronic pancreatitis accounts for 10 to 30% of cases and includes tropical pancreatitis, which is prevalent in India and Southeast Asia and is characterized by young onset, large duct stones, and a high malignancy risk. Genetic causes include PRSS1 mutations (hereditary pancreatitis, autosomal dominant with 80% penetrance and a 40% lifetime pancreatic malignancy risk by age 70), SPINK1 (a modifier gene), CFTR (heterozygous mutations), CTRC, CPA1, and CLDN2. Autoimmune pancreatitis encompasses type 1 (IgG4-related, systemic) and type 2 (idiopathic duct-centric, associated with inflammatory bowel disease). Recurrent and severe acute pancreatitis progresses to chronic pancreatitis in 36% of cases, particularly with continued alcohol use and smoking. Obstructive causes include pancreatic duct obstruction from tumors, strictures, or pancreas divisum with obstruction.

### Sentinel Acute Pancreatitis Event (SAPE) Hypothesis

The SAPE hypothesis proposes that the first attack of acute pancreatitis sensitizes pancreatic stellate cells. Subsequent insults from alcohol, smoking, or genetic modifiers then activate these stellate cells, driving fibrogenesis with progressive fibrosis, parenchymal atrophy, and calcification.

## Clinical Presentation

### Pain

Pain is the most common symptom, present in 85% of patients, and is characteristically epigastric, radiating to the back, and worsened by eating. The pattern may be constant or manifest as intermittent episodes. The concept of pain "burnout," in which pain decreases as the gland becomes completely fibrotic and calcified, is not reliably observed in clinical practice. The mechanisms of pain in chronic pancreatitis are multifactorial and include ductal hypertension, oxidative stress, neuronal inflammation (neuropathy), and central sensitization. An important clinical observation is that pain correlates poorly with the severity of imaging findings.

### Exocrine Insufficiency

Steatorrhea develops when more than 90% of exocrine function is lost and leads to fat-soluble vitamin deficiency (vitamins A, D, E, and K). Fat malabsorption is more clinically significant than protein or carbohydrate malabsorption. Patients experience weight loss, malnutrition, and sarcopenia. Osteoporosis and osteopenia affect 25 to 75% of chronic pancreatitis patients.

### Endocrine Insufficiency (Type 3c Diabetes)

Type 3c diabetes develops in 40 to 50% of chronic pancreatitis patients over time. It is characterized by both insulin and glucagon deficiency, resulting in a "brittle" diabetes with a significant risk of hypoglycemia. This distinguishes it from type 2 diabetes, as patients with type 3c diabetes retain insulin sensitivity but lack glucagon-mediated counter-regulatory mechanisms, making hypoglycemia a greater concern. Treatment often requires insulin; metformin may be appropriate for mild hyperglycemia, and incretin-based therapies are under investigation.

## Diagnosis

### Imaging

CT demonstrates calcifications (95% specific for chronic pancreatitis), ductal dilation, and parenchymal atrophy, with a sensitivity of 75 to 90% for moderate-to-severe disease, though it may miss early disease. MRCP with secretin stimulation provides detailed evaluation of ductal morphology including main duct dilation, side branch ectasia, and strictures. Secretin administration enhances the sensitivity of the examination. The Cambridge classification stages ductal changes as normal, equivocal, mild, moderate, or severe.

Endoscopic ultrasonography is the most sensitive test for early chronic pancreatitis. The Rosemont classification evaluates both parenchymal criteria (hyperechoic foci, hyperechoic strands, lobularity, and cysts) and ductal criteria (dilation, irregularity, hyperechoic walls, visible side branches, and stones). Five or more criteria are consistent with chronic pancreatitis, 3 to 4 are suggestive (indeterminate), and 0 to 2 are normal. A limitation of EUS is moderate interobserver variability, and specificity declines with age, obesity, and alcohol use. Plain radiography may demonstrate pancreatic calcifications, which are found in 30% of chronic pancreatitis cases and are highly specific.

### Functional Testing

Fecal elastase-1 is the first-line non-invasive test for exocrine insufficiency: values below 200 mcg/g are suggestive and below 100 mcg/g are diagnostic of severe insufficiency. It is widely available and simple to perform, though results can be falsely low in the setting of watery diarrhea. The 72-hour fecal fat test, measuring excretion greater than 7 grams per day on a 100-gram fat diet, is the gold standard but is cumbersome and rarely performed. The 13C-mixed triglyceride breath test remains primarily a research tool with limited availability. Direct pancreatic function tests, such as the secretin stimulation test with duodenal fluid collection, represent the gold standard but are invasive and available at very few centers. A serum trypsinogen level below 20 ng/mL is highly specific for advanced chronic pancreatitis with exocrine insufficiency.

<image>A diagnostic imaging comparison for chronic pancreatitis showing four panels. Panel 1 "CT Abdomen": axial CT showing a calcified pancreas with multiple parenchymal and intraductal calcifications, dilated main pancreatic duct (chain of lakes pattern), and parenchymal atrophy. Label calcifications, dilated duct, and atrophic parenchyma with arrows. Panel 2 "MRCP with Secretin": coronal MRCP showing irregular main pancreatic duct with alternating strictures and dilations (chain of lakes), dilated side branches, and reduced ductal filling after secretin stimulation compared to normal. Show a comparison normal MRCP inset. Panel 3 "EUS": endoscopic ultrasound image showing hyperechoic foci (bright dots), hyperechoic strands, lobularity of parenchyma, dilated main pancreatic duct with hyperechoic duct walls, and a shadowing calcification. Label each Rosemont criterion feature. Panel 4 "Cambridge Classification" staging: show a series of pancreatic duct diagrams from normal (smooth duct, fine side branches) to severe (grossly irregular duct with chain of lakes, strictures, cavities, calcifications, and duct obstruction) with stages labeled (normal, equivocal, mild, moderate, severe). Use grayscale for CT/EUS panels and appropriate MR signal intensity for MRCP panel.</image>

## Management

### Pain Management — Multimodal Approach

#### Lifestyle Modification

Alcohol cessation reduces pain progression and, while it does not reverse structural damage, slows disease progression. Smoking cessation is equally important, as it reduces pain episodes and progression. Small, frequent, low-fat meals are recommended to minimize postprandial pancreatic stimulation.

#### Pharmacologic

Acetaminophen is the first-line analgesic. NSAIDs serve as second-line agents with appropriate renal monitoring. Pregabalin or gabapentin targets the neuropathic pain component, with pregabalin at 75 to 150 mg twice daily having demonstrated benefit in the Olesen randomized controlled trial. Low-dose tricyclic antidepressants, particularly amitriptyline or nortriptyline, are useful for chronic pain management. Opioids represent a last resort given the high risk of dependence in chronic pancreatitis patients (25 to 50%); when necessary, long-acting formulations with structured monitoring should be employed.

Pancreatic enzyme replacement therapy may reduce pain through negative feedback inhibition of CCK-releasing peptide, thereby reducing pancreatic stimulation, though the evidence is mixed. Non-enteric-coated preparations are preferred for this purpose but are less commonly available. Antioxidant therapy combining selenium, beta-carotene, methionine, vitamin C, and vitamin E showed modest pain reduction in the ANTICIPATE trial but has not been widely adopted.

#### Endoscopic Therapy

Extracorporeal shock wave lithotripsy is used to fragment obstructing main pancreatic duct stones before ERCP extraction. ERCP with stone extraction follows ESWL fragmentation, incorporating pancreatic sphincterotomy, stone retrieval, and pancreatic duct stenting for dominant strictures. Pancreatic duct stenting with 10 French plastic stents addresses dominant strictures and requires exchange every 3 to 6 months as a temporary measure over 12 to 24 months; the use of multiple simultaneous stents may improve outcomes. EUS-guided celiac plexus block, preferred over the percutaneous approach for its greater precision, involves injection of bupivacaine with triamcinolone and provides pain relief in 50 to 60% of patients at 4 to 8 weeks. The effect is temporary but may be repeated, and it is generally less effective than in pancreatic cancer pain.

#### Surgical Therapy

| Procedure | Indication | Key Features |
|---|---|---|
| Frey | Dilated duct + inflammatory head mass | Lateral pancreaticojejunostomy with local head coring; tissue-preserving |
| Puestow | Main duct dilated >7 mm | Lateral pancreaticojejunostomy; longitudinal duct opening with Roux-en-Y drainage |
| Beger | Inflammatory head mass, duct not dilated | Duodenum-preserving pancreatic head resection |
| Whipple | Head mass with biliary/duodenal obstruction or malignancy concern | Pancreaticoduodenectomy |
| TPIAT | Intractable pain (genetic/idiopathic CP) | Total pancreatectomy + islet autotransplant; 30-40% insulin independence at 5 years |

Surgical intervention should be considered when endoscopic therapy fails or is not feasible, with the specific procedure determined by anatomy. The Frey procedure (lateral pancreaticojejunostomy with local pancreatic head coring) is appropriate for patients with a dilated duct and an inflammatory head mass, as it preserves pancreatic tissue. The Puestow procedure (lateral pancreaticojejunostomy) is suitable when the main duct is dilated to more than 7 mm, involving longitudinal opening of the duct with Roux-en-Y drainage. The Beger procedure (duodenum-preserving pancreatic head resection) addresses an inflammatory head mass when the duct is not dilated. The Whipple procedure (pancreaticoduodenectomy) is indicated for an inflammatory head mass with biliary or duodenal obstruction or when there is concern for malignancy.

Total pancreatectomy with islet autotransplantation (TPIAT) is an option for patients with intractable pain, particularly those with genetic or idiopathic chronic pancreatitis. The procedure removes all pancreatic tissue, with harvested islets transplanted into the portal vein and liver. Insulin independence is achieved in 30 to 40% of patients at 5 years. The best outcomes are obtained when the procedure is performed before the development of opioid dependence, multiple prior surgeries, or advanced diabetes. TPIAT is increasingly available at specialized centers.

### Exocrine Insufficiency Treatment

Pancreatic enzyme replacement therapy is dosed based on lipase content, with a minimum of 40,000 to 50,000 USP units of lipase per meal and 25,000 units per snack. The dose should be divided, with half taken at the start of the meal and half midway through. If the response is inadequate, the dose may be increased to 75,000 to 90,000 units per meal. Available enteric-coated microsphere preparations include Creon, Zenpep, and Pancreaze. Viokace is a non-enteric-coated formulation that requires co-administration with a proton pump inhibitor. PPI co-administration with enteric-coated formulations improves enzyme efficacy by reducing gastric acid-mediated inactivation.

Fat-soluble vitamin supplementation with monitoring and replacement of vitamins A, D, E, and K is essential. Medium-chain triglyceride oil can provide supplemental calories, as MCTs are absorbed without the need for pancreatic lipase. A DEXA scan should be obtained at baseline and at follow-up intervals for osteoporosis management.

### Endocrine Insufficiency (Type 3c DM)

Insulin therapy is often required due to the combined deficiency of insulin and glucagon. Metformin may be appropriate for mild hyperglycemia, as there is no glucagon-mediated counter-regulatory concern at that level. Sulfonylureas should be avoided due to the high risk of hypoglycemia in the glucagon-deficient state. Hemoglobin A1c targets should be individualized, with caution exercised regarding targets below 7% in patients with hypoglycemia unawareness.

## Autoimmune Pancreatitis

### Type 1 (IgG4-Related Disease)

Type 1 autoimmune pancreatitis predominantly affects elderly males and demonstrates elevated serum IgG4 (greater than 135 mg/dL) in 75 to 80% of cases, though this marker is neither perfectly sensitive nor specific. Imaging characteristically reveals a "sausage-shaped" diffusely enlarged pancreas with loss of normal lobulation, a peripancreatic "capsule-like" rim, and delayed enhancement. Other organ involvement is common and may include sclerosing cholangitis (IgG4-SC), retroperitoneal fibrosis, sialadenitis, tubulointerstitial nephritis, and orbital pseudotumor.

Histologically, the hallmarks are a lymphoplasmacytic infiltrate with greater than 10 IgG4-positive plasma cells per high-power field, storiform fibrosis, and obliterative phlebitis. The disease responds dramatically to corticosteroids (prednisone 40 mg per day for 4 weeks followed by a taper over 2 to 3 months), but relapse occurs in 30 to 50% of cases. Maintenance therapy with azathioprine or rituximab is used for patients who relapse.

### Type 2 (Idiopathic Duct-Centric Pancreatitis)

Type 2 autoimmune pancreatitis affects younger patients without a gender predilection and is characterized by normal serum IgG4 levels. The histologic hallmark is the granulocytic epithelial lesion, defined by neutrophilic infiltration and destruction of duct epithelium. There is no other organ involvement, but an association with inflammatory bowel disease is present in 15 to 30% of cases. The disease responds to corticosteroids and rarely relapses.

### Distinguishing AIP from Pancreatic Cancer

The distinction between autoimmune pancreatitis and pancreatic cancer represents a critical diagnostic challenge, as both may present with a pancreatic mass or stricture and obstructive jaundice. An IgG4 level exceeding twice the upper limit of normal is more specific but still not 100% reliable. EUS-guided fine-needle aspiration or biopsy should be performed to rule out malignancy and may include IgG4 immunostaining of the tissue specimen. A 2-week trial of prednisone with imaging reassessment may be considered, but only after cancer has been thoroughly excluded, as a dramatic response supports the diagnosis of autoimmune pancreatitis. If any doubt about malignancy persists, surgical resection should proceed without delay.

<image>A comparison diagram between autoimmune pancreatitis type 1 and type 2. Two columns with a header row. Column 1 "Type 1 (IgG4-Related)": demographics (elderly male), serum IgG4 (elevated in 75-80%), imaging (diffusely enlarged "sausage" pancreas with capsule-like rim on CT with contrast, or focal mass), histology (lymphoplasmacytic infiltrate with abundant IgG4+ plasma cells, storiform fibrosis, obliterative phlebitis — illustrate each with a small histologic sketch), other organ involvement (list with small icons: sclerosing cholangitis, retroperitoneal fibrosis, sialadenitis, tubulointerstitial nephritis), IBD association (rare), relapse rate (30-50%). Column 2 "Type 2 (Duct-Centric)": demographics (younger, either sex), serum IgG4 (normal), imaging (focal or diffuse enlargement, similar to type 1), histology (granulocytic epithelial lesion with neutrophils destroying duct epithelium — small histologic sketch showing GEL), other organ involvement (none), IBD association (15-30%), relapse rate (rare). Central divider showing shared features: both respond to corticosteroids, both can mimic pancreatic cancer, both show pancreatic enlargement. Include a "KEY DISTINCTION" box at bottom: "Always exclude pancreatic cancer before initiating steroid trial."</image>

## Complications and Long-Term Considerations

### Pseudocyst

Pseudocysts occur in 20 to 40% of chronic pancreatitis patients and should be drained only when symptomatic, causing pain, obstruction, or infection. EUS-guided transmural drainage is the preferred approach.

### Biliary/Duodenal Obstruction

Common bile duct stricture from an inflammatory head mass occurs in 10 to 30% of patients. Endoscopic stenting serves as a bridge therapy, while surgical hepaticojejunostomy or Whipple procedure provides definitive management.

### Pancreatic Cancer Risk

Chronic pancreatitis confers a 4- to 8-fold increased risk of pancreatic cancer over the general population. Hereditary pancreatitis from PRSS1 mutations carries a 40% lifetime risk, and screening with annual MRI/MRCP with or without EUS is recommended starting at age 40. Tropical pancreatitis carries a similarly elevated risk. Screening in non-hereditary chronic pancreatitis is not established, as no proven mortality benefit has been demonstrated.

### Malnutrition and Sarcopenia

Malnutrition and sarcopenia are prevalent (30 to 50%) and associated with poor outcomes. Regular nutritional assessment, PERT optimization, vitamin and mineral supplementation, and involvement of a registered dietitian are essential components of comprehensive care.

## Key Clinical Pearls
- Smoking is an independent risk factor for CP and accelerates progression — cessation is as important as alcohol abstinence
- Fecal elastase <100 mcg/g is highly specific for severe exocrine insufficiency — first-line non-invasive test
- PERT dosing: minimum 40,000-50,000 lipase units per meal; titrate up if symptoms persist; add PPI to improve efficacy
- Type 3c diabetes (pancreatogenic) differs from type 2: combined insulin + glucagon deficiency creates brittle diabetes with high hypoglycemia risk
- EUS is the most sensitive test for early chronic pancreatitis but has moderate interobserver variability — interpret in clinical context
- Total pancreatectomy with islet autotransplantation (TPIAT) is an option for intractable pain in select patients — best outcomes when performed early before opioid dependence
- AIP type 1 (IgG4-related) can mimic pancreatic cancer — always exclude malignancy before steroid trial
- Hereditary pancreatitis (PRSS1 mutations): 40% lifetime risk of pancreatic cancer; surveillance recommended starting age 40

## References
1. Singh VK, et al. ACG Clinical Guideline: Diagnosis and Management of Chronic Pancreatitis. *Am J Gastroenterol*. 2024;119(7):1172-1195.
2. Whitcomb DC, et al. Chronic pancreatitis: an international draft consensus proposal for a new mechanistic definition. *Pancreatology*. 2016;16(2):218-224.
3. Shimosegawa T, et al. International consensus diagnostic criteria for autoimmune pancreatitis. *Pancreas*. 2011;40(3):352-358.
4. Bellin MD, et al. Total pancreatectomy with islet autotransplantation: summary of an NIDDK workshop. *Ann Surg*. 2015;261(1):21-29.
5. Olesen SS, et al. Pregabalin reduces pain in patients with chronic pancreatitis in a randomized, controlled trial. *Gastroenterology*. 2011;141(2):536-543.